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Background: Pseudomyogenic hemangioendothelioma (PHE) is an unusual vascular tumor of intermediate
malignancy that rarely metastasizes and tends to arise in the lower limbs of young adults and children. Histologically,
PHE shows fascicular proliferation of eosinophilic spindle cells and/or epithelioid cells showing “pseudomyogenic”
morphology. Immunohistochemically, PHE is usually positive for vimentin, cytokeratin, CD31 and ERG.
Method: We examined FOSB immunohistochemistry (IHC) in 27 cases consisting of 4 PHE and its histologic
mimics including 6 epithelioid hemangioendotheliomas (EHE), 8 angiosarcomas (AS), 4 Kaposi sarcomas (KS)
and 5 epithelioid sarcomas (ES). In addition, we performed IHC of CAMTA1 which has recently been established
as a useful marker of EHE. We elucidated the diagnostic utility of FOSB IHC in the differential diagnosis of PHE
and its histological mimics and also examined the usefulness of FOSB and CAMTA1 IHC combination in the differential
diagnosis of the tumors.
Results: IHC revealed diffuse and strong FOSB expression in all PHE cases, while the other tumor types demonstrated
limited, weak or no FOSB expression. All EHE cases exhibited diffuse and moderate to strong expression of CAMTA1.
All tumor types except for EHE showed limited, weak or no CAMTA1 reactivity.
Conclusions: Diffuse and strong FOSB expression was specific for PHE in the current series and FOSB IHC
is an effective tool for differentiating between PHE and its histological mimics. Moreover, the combination
of FOSB and CAMTA1 IHC is useful for distinguishing PHE from EHE.
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Pseudomyogenic hemangioendothelioma (PHE) is an
unusual soft tissue tumor, defined as a vascular tumor
of intermediate malignancy that rarely metastasizes in the
current World Health Organization (WHO) classification
of soft tissue and bone tumors [1]. PHE mainly affects
young adults and children with a remarkable male pre-
dominance. PHE tends to arise in the lower limbs,* Correspondence: hasetada@sapmed.ac.jp
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Histologically, PHE consists of fascicular proliferation
of spindle-shaped and/or epithelioid cells with oval to
short-spindle nuclei and abundant eosinophilic cyto-
plasm showing “pseudomyogenic” morphology. Immu-
nohistochemically, the tumor cells are usually positive
for vimentin, cytokeratin, and some vascular markers
including ERG and CD31, but they are negative for
desmin and exhibited no myogenic differentiation.
PHE has also been termed epithelioid sarcoma-like
hemangioendothelioma according to its morphological
similarity to epithelioid sarcoma (ES) by Billings et al. [2].le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Fig. 1 Representative histologic findings of PHE. a PHE consisted of fascicular proliferation of bland, spindle-shaped cells that had oval nuclei
and obvious eosinophilic cytoplasm showing pseudomyogenic differentiation. b Rhabdomyoblast-like cells with abundant eosinophilic cytoplasm
were sparsely observed. Epithelioid cells were also found
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hemangoendothelioma, showing solid sheet and nest pro-
liferation of round to slightly spindle cells with prominent
eosinophilic cytoplasm. The tumor cells showed diffuse
and strong cytokeratin expression on immunohistochem-
istry (IHC) and, therefore, they emphasized the import-
ance of distinguishing between PHE and ES.
Even though PHE has some characteristic histological
features, we may have difficulty in distinguishing PHEFig. 2 Representative histologic findings of EHE, AS, KS and ES. a EHE showed
fascicular proliferation of spindle-shaped cells that occasionally had intracytop
composed of solid and partly gland-like proliferation of spindle and/or epithe
This case showed prominent epithelioid morphology and was diagnosed as e
consisted of fascicular proliferation of endothelial spindle cells focally forming
of spindle-shaped and epithelioid cells with oval nuclei with moderate nucleafrom histologically similar vascular and epithelioid tumors
of soft tissue including epithelioid hemangioendothelioma
(EHE), angiosarcoma (AS), Kaposi sarcoma (KS) and ES,
especially with small biopsy specimens. The precise diag-
nosis of PHE and distinguishing it from similar tumors is
very important because the clinical behavior and malig-
nant potential of these tumors are very different. We often
use an IHC panel containing several vascular and epithe-
lial markers for making the differential diagnosis of thesebland morphology that resembled PHE cases and consisted of
lasmic lumina, with the appearance of primitive vessels. b AS was
lioid cells showing severe nuclear atypia and frequent mitotic figures.
pithelioid AS. c KS exhibited multilobulated vascular lesions that
a vascular channel. d ES consisted of fascicular and solid proliferation
r atypia




Histology Location FOSB CAMTA1
% Intensity % Intensity
1 20/F PHE Bone (mul)a 100 Strong - -
2 36/M PHE Bone (mul)a 100 Strong NA NA
3 15/F PHE Thigh 100 Strong - -
4 54/M PHE Calcaneus 100 Strong - -
5 62/F EHE Forehead - - 100 Moderate
6 71/F EHE Femur 10 Weak 100 Moderate
7 73/F EHE Liver (mul) - - 100 Strong
8 86/F EHE Upper arm 10 Weak 100 Strong
9 68/F EHE Forearm 10 Weak 100 Strong
10 32/M EHE Liver (mul) - - 100 Strong
11 72/M AS Vertebra 10 Weak - -
12 48/M AS Humerus 10 Weak 10 Weak
13 89/M AS Head - - 10 Weak
14 62/F AS Head 10 Weak - -
15 70/M AS Head 10 Weak 10 Weak
16 82/F AS Head - - - -
17 74/F AS Upper arm 10 Weak 10 Weak
18 77/M AS Head 10 Weak 10 Weak
19 89/F KS Trunk, limbs
(mul)
10 Weak - -
20 68/M KS Trunk, limbs
(mul)
10 Weak 10 Weak
21 76/M KS Larynx, limbs
(mul)
10 Weak - -
22 82/M KS Limbs (mul) 10 Weak - -
23 75/F ES Thigh 10 Weak - -
24 73/F ES Thigh 10 Weak - -
25 55/M ES Forearm - - - -
26 30/M ES Thigh 10 Weak - -
27 80/F ES Genital region - - - -
Abbreviations: PHE pseudomyogenic hemangioendothelioma, EHE epithelioid
hemangioendothelioma, AS angiosarcoma, KS Kaposi sarcoma, ES epithelioid
sarcoma, mul multiple lesion; -, negative, NA not available
aThe patients (Case 1, 2) had multiple bone lesions in one lower limb
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immunoreactivity for these markers which sometimes
makes it challenging to diagnose PHE. EHE is the most
important tumor in the differential diagnosis of PHE,
because its histological findings and clinical presentation
are similar to those of PHE. Both of them usually show a
fascicular proliferation of relatively bland spindle and/or
epithelioid cells with eosinophilic cytoplasm. In addition,
PHE tends to emerge with multiple musculoskeletal
lesions, often involving skeletal bones [3] and EHE also
has a tendency to form multifocal lesions in the bone.
Some studies have clarified specific fusions of WWTR1-
CAMTA1 or YAP1-TFE3 in EHE [4, 5]. The WWTR1-CA
MTA1 fusion derived from translocation of t(1;3)(p36;q25)
and was often observed in most EHE cases. Moreover,
recent studies revealed that the specific nuclear expression
of CAMTA1 on IHC was a useful tool for the diagnosis of
EHE [6, 7]. Alternatively, some studies revealed a specific
SERPINE1-FOSB fusion derived from t(7;19)(q22;q13) and
significantly higher FOSB mRNA expression in PHE tumor
cells [8, 9]. Thus, FOSB is predicted to be a specific
marker of PHE, although FOSB IHC in PHE has not
been reported in detail.
In the present study, we elucidated the diagnostic
utility of FOSB IHC in the differential diagnosis of
PHE and its histological mimics including EHE, AS,
KS and ES. We also performed CAMTA1 IHC, an ex-
cellent diagnostic marker for EHE [6, 7], and exam-
ined whether a combination of FOSB and CAMTA1 is
useful for distinguishing these tumors.
Methods
Patients and pathological evaluation
For IHC, we chose 27 cases consisting of 4 PHEs, 6 EHEs,
8 ASs, 4 KSs, and 5 ESs from the pathology files of
the Department of Surgical Pathology, Sapporo Medical
University Hospital, Sapporo, Japan. We used biopsy or
resected specimens in various sites for the study. We
reviewed all hematoxylin and eosin sections and checked
previously performed IHC findings. After we confirmed
that each case fulfilled the histological criteria and the
results of IHC were consistent with each tumor type
described above, we selected representative sections suit-
able for IHC.
In brief, PHE consisted of fascicular proliferation of
bland, spindle-shaped cells that have oval nuclei and
obvious eosinophilic cytoplasm showing myogenic differen-
tiation (Fig. 1). On IHC, the tumor cells were positive for
cytokeratin AE1/AE3, CD31 and ERG, and were negative
for myogenic makers including desmin and muscle specific
actin HHF35. EHE also showed a bland morphology
like PHE cases and consisted of fascicular proliferation of
spindle-shaped cells, and occasionally had intracytoplasmic
lumina, with an appearance like primitive vessels (Fig. 2a).Focally, the tumor had a myxoid stroma. The tumor cells
of PHE were positive for epithelial and vascular markers on
IHC. AS exhibited an apparent malignant morphology and
was composed of solid and partly gland-like proliferation of
spindle and/or epithelioid cells showing severe nuclear
atypia and frequent mitotic figures. Some cases showed
prominent epithelioid morphology and had been diagnosed
as epithelioid AS (Fig. 2b). The tumor cells were positive
for epithelial and vascular markers. KS exhibited multilobu-
lated vascular lesions that consisted of fascicular prolifera-
tion of endothelial spindle cells with focal vascular channel
formation in the dermis to subcutis (Fig. 2c). The tumor
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CD34, ERG and D2-40. All KS patients had no HIV infec-
tion, although they were in a compromised situation
because of major surgery or long-term steroid medication,
and showed nuclear HHV-8 reactivity in the tumor cells
on IHC. ES consisted of fascicular and solid proliferation
of spindle-shaped and epithelioid cells with oval nuclei
and moderate nuclear atypia. The tumor cells were posi-
tive for AE1/AE3, epithelial membrane antigen (EMA)
and CD34. The tumor cells were negative for INI1.
FOSB and CAMTA1 immunohistochemistry
IHC was performed using primary rabbit monoclonal
FOSB antibody (clone 5G4, dilution 1:100, Cell Signaling
Technology, Danvers, MA) and rabbit polyclonal CAMTA1
antibody (dilution 1:1000, Atlas Antibodies, Stockholm,
Sweden). All slides were loaded into a PT Link module
(Dako, Carpinteria, CA) and subjected to an antigen
retrieval/dewaxing protocol with EnVision FLEX Target
Retrieval Solution (Dako) with pH 6.0 citrate buffer (FOSB)
or pH 9.0 EDTA buffer (CAMTA1) before being trans-
ferred to an Autostainer Link 48 instrument (Dako). We
then assessed the immunoreactivity of FOSB and CAMTA1
only if the tumor cells showed nuclear immunoreactivity.
We semiquantitatively estimated the immunoreactivityFig. 3 Immunohistochemistry of FOSB and CAMTA1. a Tumor cells of PHE
b Tumor cells of PHE showed diffuse and strong nuclear expression of FOS
decalcification. Positivity of FOSB was preserved after the decalcification pr
expression. Its positivity was apparently different from that in PHE. Epiderm
for FOSB. These findings should be carefully distinguished from true FOSB
diffuse and strong nuclear expression of CAMTA1 (Case 9)according to the percentage of positive tumor cells appro-
ximately within a range of 10 %, and staining intensity was
graded as weak, moderate or strong. Immunoreactivity was
estimated by two observers (S.S. and T.H.).
Results
Clinical information is summarized in Table 1. Patients’
age and sex were widely distributed. Three PHE cases
showed bone lesions and 2 of them (Case 1, 2) had mul-
tiple bone lesions in one lower limb. Six EHE cases
affected the liver (2 cases), bone (1 case), head (1 case)
and extremities (2 case). Two cases with involvement of
the liver (Case 7, 10) had multiple liver nodules. Five of 8
AS cases had involvement of the head, and bone was
affected in 2 AS cases. All KS cases demonstrated multiple
purpura in the extremities and/or trunk. The extremities
were affected in all ES cases except for 1 genital case.
On IHC (Table 1), diffuse and strong expression of
FOSB was observed in all PHE cases (Fig. 3a, b), while the
other tumor types including 3 EHE, 6 AS, 4 KS and 3 ES
cases demonstrated limited (10 %) and weak FOSB
expression (Fig. 3c). Epidermal keratinocytes and endothe-
lial cells in the background also showed weak FOSB
expression although the intensity of FOSB expression in
these cells was apparently different from that in PHEshowed diffuse and strong nuclear expression of FOSB (Case 3).
B. This section was obtained from a bone lesion and underwent
ocess (Case 4). c Tumor cells of KS showed limited and weak FOSB
al keratinocytes and endothelial cells in the background were positive
positivity in tumor cells (Case 22). d Tumor cells of EHE exhibited
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2 AS and 2 ES cases. On the other hand, all EHE cases
exhibited diffuse and moderate to strong expression of
CAMTA1 (Fig. 3d). Five AS and 1 KS showed limited
(10 %) and weak CAMTA1 expression. All PHE cases
except for 1 with missing available slides were negative for
CAMTA1. Moreover, 3 AS, 3 KS and 5 ES cases exhibited
no CAMTA1 expression.
Discussion
Some studies revealed that PHE has a novel fusion gene of
SERPINE1-FOSB derived from translocation of t(7;19)
(q22;q13) and established PHE as a genetically distinct
entity [8, 9]. Walther et al. also demonstrated that FOSB
mRNA expression in PHE cases was significantly higher
than other soft tissue tumor cases, and predicted that
SERPINE1-FOSB fusion provided a promoter that allowed
the strong expression of FOSB [9]. Ide et al. have recently
reported a rare penile PHE case with SERPINE1-FOSB
fusion detected by RT-PCR [10], and demonstrated strong
nuclear expression of FOSB on IHC in the tumor cells. In
our study, only PHE cases showed diffuse and strong posi-
tivity for FOSB, while cases of EHE, AS, KS and ES exhi-
bited limited or no expression of FOSB on IHC. There
was a notable difference of FOSB positivity between PHE
and other tumor types. Furthermore, FOSB showed well-
defined nuclear expression and its reactivity was preserved
in specimens from decalcified bone. This suggested that
FOSB is a specific marker of PHE and FOSB IHC is a
convenient and effective tool for excluding PHE from
other vascular and epithelioid tumors of the soft tissue.
Moreover, all PHE cases except for 1 with missing avai-
lable slides were negative for CAMTA1. On the contrary,
all EHE cases demonstrated diffuse and moderate to
strong CAMTA1 expression without strong FOSB reacti-
vity. Based on the results, the combination of FOSB and
CAMTA1 IHC could be a useful diagnostic tool for distin-
guishing PHE from EHE.
FOSB expression was often observed in various back-
ground cells which often intermingled with tumor cells;
therefore, such positivity in background cells may have
misled us into placing a higher valuation of FOSB expres-
sion. FOSB is one of the transcription factors of the FOS
family proteins that regulate cell proliferation and diffe-
rentiation. The FOSB protein can form dimers with
proteins of the JUN family and they consist of major com-
ponents of activating protein 1 complex that regulates
various kinds of gene expression. Several reports have
described FOSB expression in normal tissues on IHC.
FOSB expression was detected in normal epithelial cells of
mammary lobules and terminal duct, and stromal fibro-
blasts in mammary gland tissue [11]. FOSB is also
expressed in intermediate trophoblasts in the placenta
[12] and epidermal keratinocytes of the skin [13]. Inaddition, FOSB is widely expressed in bony and cartila-
ginous tissue in developing bone, whisker follicles, liver,
and epidermal tissue in fetal mice [14]. In the present
study, FOSB was sometimes expressed in endothelial cells,
keratinocytes of the epidermis and hair follicles, and some
stromal fibroblasts. Therefore, we had some difficulty in
estimating the true FOSB positivity in tumor cells except
for PHE. We could precisely estimate FOSB expression
in tumor cells because the intensity of FOSB expression
in background cells was stronger than that in tumor cells
in EHE, AS, KS and ES cases which showed limited, weak
or no reactivity of FOSB. In addition, the reactivity was
obviously weaker than that in PHE tumor cells. We
should check HE stained sections corresponding to IHC
specimens to confirm whether FOSB-positive cells are
tumor cells. Moreover, such background cells would be a
useful internal positive control for FOSB IHC if we could
carefully assess the true positivity of FOSB.
Conclusion
Diffuse and strong FOSB expression was specific for PHE
in the current series and FOSB IHC is an effective tool in
the differential diagnosis of PHE. Moreover, the combi-
nation of FOSB and CAMTA1 IHC is a useful panel for
distinguishing PHE from EHE.
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